Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

Trial Profile

Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms FAST-AR
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Oct 2015 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
    • 29 Oct 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top